Shots: The ODD is based on Omeros’ P-III program assessing OMS721 in patients with HSCT-TMA. Additionally, OMS721 is being evaluated in ongoing P-III program for IgA nephropathy, and aHUS respectively With the above designation OMS721 will serve in both prevention and treatment of HSCT-TMA in EU and the US. OMS721 also received ODD in IgA […]Read More
Tags : Omeros’
Latest Posts
Categories
Related Topics
AbbVie
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
EU
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US